Health Catalyst, Inc. (HCAT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Health Catalyst, Inc. (HCAT) stock price & volume — 10-year historical chart
Health Catalyst, Inc. (HCAT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Health Catalyst, Inc. (HCAT) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 12, 2026 | $0.08vs $0.09-11.1% | $75Mvs $74M+1.0% |
| Q4 2025 | Nov 10, 2025 | $0.06vs $0.05+20.0% | $76Mvs $74M+3.0% |
| Q3 2025 | Aug 7, 2025 | $0.04vs $0.03+33.3% | $81Mvs $85M-5.2% |
| Q2 2025 | May 7, 2025 | $0.01vs $0.01+0.0% | $79Mvs $79M+0.3% |
Health Catalyst, Inc. (HCAT) competitors in Healthcare Data, Analytics and AI — business model, growth, and fundamentals comparison
Health Catalyst, Inc. (HCAT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Health Catalyst, Inc. (HCAT) annual income statement — 10-year revenue, gross profit & net income history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 73.08M | 112.57M | 154.94M | 188.84M | 241.93M | 276.24M | 295.94M | 306.58M | 311.14M |
| Revenue Growth % | - | 54.04% | 37.63% | 21.88% | 28.11% | 14.18% | 7.13% | 3.6% | 1.48% |
| Cost of Goods Sold | 43.64M | 59.85M | 75.34M | 98.08M | 124.35M | 143.05M | 164.1M | 165.81M | 159.46M |
| COGS % of Revenue | 59.72% | 53.17% | 48.63% | 51.94% | 51.4% | 51.79% | 55.45% | 54.08% | 51.25% |
| Gross Profit | 29.44M▲ 0% | 52.72M▲ 79.1% | 79.6M▲ 51.0% | 90.77M▲ 14.0% | 117.57M▲ 29.5% | 133.19M▲ 13.3% | 131.83M▼ 1.0% | 140.78M▲ 6.8% | 151.68M▲ 7.7% |
| Gross Margin % | 40.28% | 46.83% | 51.37% | 48.06% | 48.6% | 48.21% | 44.55% | 45.92% | 48.75% |
| Gross Profit Growth % | - | 79.09% | 50.97% | 14.04% | 29.53% | 13.28% | -1.02% | 6.79% | 7.74% |
| Operating Expenses | 74.98M | 112.82M | 134.46M | 186.89M | 261.22M | 273.19M | 258.73M | 210.59M | 153.07M |
| OpEx % of Revenue | 102.6% | 100.22% | 86.78% | 98.97% | 107.98% | 98.9% | 87.43% | 68.69% | 49.2% |
| Selling, General & Admin | 40.62M | 66.81M | 79M | 114.65M | 160.96M | 149.22M | 143.88M | 111.2M | 102.04M |
| SG&A % of Revenue | 55.58% | 59.35% | 50.99% | 60.71% | 66.53% | 54.02% | 48.62% | 36.27% | 32.79% |
| Research & Development | 28.47M | 38.59M | 46.25M | 53.52M | 62.73M | 75.68M | 72.63M | 57.95M | 49.77M |
| R&D % of Revenue | 38.96% | 34.28% | 29.85% | 28.34% | 25.93% | 27.4% | 24.54% | 18.9% | 16% |
| Other Operating Expenses | -4K | -39K | 9.21M | 18.73M | 37.53M | 48.3M | 42.22M | 41.43M | 1.26M |
| Operating Income | -45.54M▲ 0% | -60.09M▼ 32.0% | -54.87M▲ 8.7% | -96.13M▼ 75.2% | -143.65M▼ 49.4% | -140M▲ 2.5% | -126.9M▲ 9.4% | -69.81M▲ 45.0% | -160.85M▼ 130.4% |
| Operating Margin % | -62.31% | -53.38% | -35.41% | -50.9% | -59.38% | -50.68% | -42.88% | -22.77% | -51.7% |
| Operating Income Growth % | - | -31.96% | 8.7% | -75.2% | -49.44% | 2.54% | 9.36% | 44.99% | -130.43% |
| EBITDA | -39.65M | -52.68M | -45.65M | -77.4M | -102.54M | -88.48M | -84.67M | -28.38M | -110.35M |
| EBITDA Margin % | -54.25% | -46.8% | -29.46% | -40.99% | -42.38% | -32.03% | -28.61% | -9.26% | -35.47% |
| EBITDA Growth % | - | -32.88% | 13.34% | -69.54% | -32.48% | 13.71% | 4.3% | 66.49% | -288.91% |
| D&A (Non-Cash Add-back) | 5.89M | 7.41M | 9.21M | 18.73M | 41.11M | 51.53M | 42.22M | 41.43M | 50.5M |
| EBIT | -45.54M | -60.09M | -56.53M | -104.64M | -142.79M | -134.44M | -110.5M | -52.08M | 0 |
| Net Interest Income | -1.47M | -1.99M | -3.45M | -11.62M | -16.48M | -1.55M | 9.1M | 896K | 0 |
| Interest Income | 542K | 602K | 2.81M | 2.09M | 831K | 5.69M | 16.39M | 17.98M | 0 |
| Interest Expense | 2.01M | 2.59M | 6.26M | 13.72M | 17.31M | 7.24M | 7.29M | 17.09M | -16.4M |
| Other Income/Expense | -1.47M | -2.02M | -5.09M | -20.09M | -16.46M | -1.68M | 9.11M | 637K | -16.4M |
| Pretax Income | -47.01M▲ 0% | -62.12M▼ 32.1% | -59.95M▲ 3.5% | -116.21M▼ 93.8% | -160.11M▼ 37.8% | -141.68M▲ 11.5% | -117.79M▲ 16.9% | -69.17M▲ 41.3% | -177.26M▼ 156.3% |
| Pretax Margin % | -64.32% | -55.18% | -38.69% | -61.54% | -66.18% | -51.29% | -39.8% | -22.56% | -56.97% |
| Income Tax | 26K | -135K | 142K | -1.19M | -6.9M | -4.28M | 356K | 333K | 716K |
| Effective Tax Rate % | -0.06% | 0.22% | -0.24% | 1.03% | 4.31% | 3.02% | -0.3% | -0.48% | -0.4% |
| Net Income | -47.03M▲ 0% | -61.98M▼ 31.8% | -60.1M▲ 3.0% | -115.02M▼ 91.4% | -153.21M▼ 33.2% | -137.4M▲ 10.3% | -118.15M▲ 14.0% | -69.5M▲ 41.2% | -177.97M▼ 156.1% |
| Net Margin % | -64.36% | -55.06% | -38.79% | -60.91% | -63.33% | -49.74% | -39.92% | -22.67% | -57.2% |
| Net Income Growth % | - | -31.78% | 3.05% | -91.39% | -33.21% | 10.32% | 14.01% | 41.17% | -156.07% |
| Net Income (Continuing) | -47.03M | -61.98M | -60.1M | -115.02M | -153.21M | -137.4M | -118.15M | -69.5M | -177.97M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.69▲ 0% | -2.23▼ 32.0% | -3.21▼ 43.9% | -2.91▲ 9.3% | -3.23▼ 11.0% | -2.54▲ 21.4% | -2.09▲ 17.7% | -1.15▲ 45.0% | -2.55▼ 121.7% |
| EPS Growth % | - | -31.95% | -43.95% | 9.35% | -11% | 21.36% | 17.72% | 44.98% | -121.74% |
| EPS (Basic) | -1.69 | -2.23 | -3.21 | -2.91 | -3.23 | -2.56 | -2.09 | -1.15 | -2.55 |
| Diluted Shares Outstanding | 27.77M | 27.77M | 18.74M | 39.54M | 47.49M | 54.08M | 56.42M | 60.19M | 69.9M |
| Basic Shares Outstanding | 27.77M | 27.77M | 18.74M | 39.54M | 47.49M | 53.72M | 56.42M | 60.19M | 69.9M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
Health Catalyst, Inc. (HCAT) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 71.39M | 66.86M | 264.24M | 329.8M | 508.39M | 427.8M | 393.4M | 465.65M | 169.31M |
| Cash & Short-Term Investments | 51.46M | 33.19M | 228.28M | 270.87M | 444.98M | 363.49M | 317.73M | 392M | 95.73M |
| Cash Only | 22.98M | 28.43M | 18.03M | 91.95M | 193.23M | 116.31M | 106.28M | 249.65M | 50.81M |
| Short-Term Investments | 28.48M | 4.76M | 210.25M | 178.92M | 251.75M | 247.18M | 211.45M | 142.35M | 44.92M |
| Accounts Receivable | 17.05M | 27.7M | 27.57M | 48.3M | 48.8M | 47.97M | 60.29M | 57.18M | 59.13M |
| Days Sales Outstanding | 85.17 | 89.8 | 64.95 | 93.35 | 73.63 | 63.38 | 74.36 | 68.08 | 69.36 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 762K | 649K | 0 | 0 | 14.61M | 16.34M | 15.38M | 16.47M | 14.45M |
| Total Non-Current Assets | 38.88M | 44.12M | 38.12M | 247.94M | 323.7M | 324.49M | 308.42M | 393.28M | 333.34M |
| Property, Plant & Equipment | 5.38M | 11.02M | 8.08M | 37.59M | 44.45M | 42.59M | 39.64M | 41.45M | 40.48M |
| Fixed Asset Turnover | 13.58x | 10.22x | 19.17x | 5.02x | 5.44x | 6.49x | 7.47x | 7.40x | 7.69x |
| Goodwill | 3.69M | 3.69M | 3.69M | 107.82M | 169.97M | 185.98M | 190.65M | 259.76M | 209.07M |
| Intangible Assets | 29.57M | 28.3M | 25.54M | 98.92M | 104.79M | 92.19M | 73.38M | 86.05M | 77.68M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 243K | 1.1M | 810K | 3.61M | 4.5M | 3.73M | 4.74M | 6.02M | 6.11M |
| Total Assets | 110.27M▲ 0% | 110.97M▲ 0.6% | 302.36M▲ 172.5% | 577.74M▲ 91.1% | 832.1M▲ 44.0% | 752.29M▼ 9.6% | 701.81M▼ 6.7% | 858.93M▲ 22.4% | 502.64M▼ 41.5% |
| Asset Turnover | 0.66x | 1.01x | 0.51x | 0.33x | 0.29x | 0.37x | 0.42x | 0.36x | 0.62x |
| Asset Growth % | - | 0.64% | 172.46% | 91.08% | 44.03% | -9.59% | -6.71% | 22.39% | -41.48% |
| Total Current Liabilities | 30.77M | 41.81M | 48.22M | 88.04M | 93.05M | 82.51M | 89.03M | 325.85M | 89.57M |
| Accounts Payable | 833K | 1.81M | 3.62M | 5.33M | 4.69M | 4.42M | 6.64M | 11.43M | 9.36M |
| Days Payables Outstanding | 6.97 | 11.05 | 17.55 | 19.84 | 13.77 | 11.29 | 14.77 | 25.17 | 21.43 |
| Short-Term Debt | 0 | 1.29M | 2.81M | 0 | 0 | 0 | 0 | 231.18M | 5.41M |
| Deferred Revenue (Current) | 10.72M | 24.75M | 30.65M | 47.15M | 56.63M | 54.96M | 55.75M | 53.28M | 56.11M |
| Other Current Liabilities | 16.27M | 5.49M | 4.05M | 24.27M | 10.87M | 7.51M | 11.68M | 11.65M | 28.06M |
| Current Ratio | 2.32x | 1.60x | 5.48x | 3.75x | 5.46x | 5.18x | 4.42x | 1.43x | 1.89x |
| Quick Ratio | 2.32x | 1.60x | 5.48x | 3.75x | 5.46x | 5.18x | 4.42x | 1.43x | 1.89x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 338.98M | 443.94M | 53.5M | 213.6M | 216.95M | 244.77M | 245.86M | 167.87M | 167.29M |
| Long-Term Debt | 9.62M | 18.81M | 48.2M | 168.99M | 180.94M | 226.52M | 228.03M | 151.18M | 14.21M |
| Capital Lease Obligations | 872K | 4.23M | 1.65M | 23.67M | 20.24M | 18.02M | 17.68M | 16.29M | 0 |
| Deferred Tax Liabilities | 0 | -4.23M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 328.49M | 413.62M | 2.19M | 19.06M | 14.83M | 121K | 74K | 154K | 153.08M |
| Total Liabilities | 369.74M | 485.74M | 101.72M | 301.64M | 310M | 327.28M | 334.89M | 493.72M | 256.86M |
| Total Debt | 12.62M | 26.91M | 52.66M | 195.28M | 204.61M | 247.97M | 249.07M | 402.26M | 19.61M |
| Net Debt | -10.35M | -1.52M | 34.63M | 103.33M | 11.38M | 131.66M | 142.79M | 152.62M | -31.2M |
| Debt / Equity | - | - | 0.26x | 0.71x | 0.39x | 0.58x | 0.68x | 1.10x | 0.08x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -22.69x | -23.23x | -8.76x | -7.01x | -8.30x | -19.34x | -17.41x | -4.09x | - |
| Total Equity | -259.48M▲ 0% | -374.77M▼ 44.4% | 200.64M▲ 153.5% | 276.1M▲ 37.6% | 522.1M▲ 89.1% | 425.01M▼ 18.6% | 366.92M▼ 13.7% | 365.21M▼ 0.5% | 245.78M▼ 32.7% |
| Equity Growth % | - | -44.43% | 153.54% | 37.61% | 89.1% | -18.6% | -13.67% | -0.47% | -32.7% |
| Book Value per Share | -9.34 | -13.50 | 10.71 | 6.98 | 10.99 | 7.86 | 6.50 | 6.07 | 3.52 |
| Total Shareholders' Equity | -259.48M | -374.77M | 200.64M | 276.1M | 522.1M | 425.01M | 366.92M | 365.21M | 245.78M |
| Common Stock | 5K | 5K | 37K | 43K | 53K | 1.42B | 1.48B | 1.55B | 1.61B |
| Retained Earnings | -259.47M | -374.77M | -610.51M | -725.65M | -878.86M | -999.02M | -1.12B | -1.19B | -1.36B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -12K | -1K | 72K | 61K | -67K | -648K | 33K | -835K | 1.59M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Health Catalyst, Inc. (HCAT) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -36.83M | -40.3M | -32.18M | -26.15M | -23.12M | -35.27M | -33.08M | 14.56M | 731K |
| Operating CF Margin % | -50.39% | -35.8% | -20.77% | -13.85% | -9.56% | -12.77% | -11.18% | 4.75% | 0.23% |
| Operating CF Growth % | - | -9.41% | 20.13% | 18.75% | 11.57% | -52.53% | 6.21% | 144.01% | -94.98% |
| Net Income | -47.03M | -61.98M | -60.1M | -115.02M | -153.21M | -137.4M | -118.15M | -69.5M | -177.97M |
| Depreciation & Amortization | 5.89M | 7.41M | 9.21M | 18.73M | 37.53M | 48.3M | 42.22M | 41.43M | 50.5M |
| Stock-Based Compensation | 4.24M | 4.2M | 17.84M | 37.96M | 65.14M | 72.1M | 55.76M | 40.13M | 27.01M |
| Deferred Taxes | 14K | -206K | 40K | -1.27M | -7.13M | -4.52M | 8K | 77K | 81K |
| Other Non-Cash Items | 225K | 533K | 2.08M | 37.29M | 29.93M | 162K | 750K | 3.08M | 101.11M |
| Working Capital Changes | -166K | 9.75M | -1.27M | -3.83M | 4.62M | -13.91M | -13.67M | -660K | 0 |
| Change in Receivables | 4.44M | -3.63M | 127K | -16.45M | 102K | 788K | -13.66M | 4.28M | -1.81M |
| Change in Inventory | -2.56M | 2.46M | -3.65M | 0 | -8.32M | 0 | 0 | 0 | 0 |
| Change in Payables | -6.29M | 4.42M | -86K | 8.24M | 5.2M | -4.7M | 4.87M | 5.58M | -11.51M |
| Cash from Investing | 22.41M | 21.4M | -209.6M | -82.56M | -139.68M | -39.02M | 20.29M | -22.9M | 36.19M |
| Capital Expenditures | -3.34M | -2.5M | -4.33M | -10.46M | -18.47M | -2.17M | -1.24M | -1.62M | -968K |
| CapEx % of Revenue | 4.58% | 2.22% | 2.8% | 5.54% | 7.63% | 0.78% | 0.42% | 0.53% | 0.31% |
| Acquisitions | 878K | 228K | 1.94M | -101.66M | -46.76M | -27.85M | -11.39M | -80.28M | -41.11M |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -831K | -199K | -1.87M | 14K | 22K | -15.22M | -13.04M | -14.77M | -20.54M |
| Cash from Financing | 24.87M | 24.35M | 231.38M | 182.61M | 264.08M | -2.61M | 2.73M | 151.75M | -235.78M |
| Debt Issued (Net) | 9.79M | 9.95M | 25.35M | 165.44M | 0 | 0 | 0 | 151.32M | 0 |
| Equity Issued (Net) | 0 | -1000K | 1000K | 1000K | 1000K | -1000K | -1000K | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | -8.71M | 0 | 0 | 0 | -8.39M | -1.81M | 0 | -5M |
| Other Financing | 15.08M | 23.11M | -689K | -23.37M | 18.9M | 5.78M | 4.54M | -2.15M | -235.78M |
| Net Change in Cash | 10.45M▲ 0% | 5.45M▼ 47.8% | -10.4M▼ 290.7% | 73.92M▲ 810.9% | 101.27M▲ 37.0% | -76.92M▼ 175.9% | -10.04M▲ 87.0% | 143.37M▲ 1528.5% | -198.83M▼ 238.7% |
| Free Cash Flow | -40.17M▲ 0% | -42.8M▼ 6.5% | -36.52M▲ 14.7% | -36.61M▼ 0.3% | -41.59M▼ 13.6% | -52.68M▼ 26.7% | -47.39M▲ 10.0% | -1.84M▲ 96.1% | -237K▲ 87.1% |
| FCF Margin % | -54.97% | -38.02% | -23.57% | -19.39% | -17.19% | -19.07% | -16.01% | -0.6% | -0.08% |
| FCF Growth % | - | -6.54% | 14.68% | -0.26% | -13.59% | -26.67% | 10.05% | 96.12% | 87.11% |
| FCF per Share | -1.45 | -1.54 | -1.95 | -0.93 | -0.88 | -0.97 | -0.84 | -0.03 | -0.00 |
| FCF Conversion (FCF/Net Income) | 0.78x | 0.65x | 0.54x | 0.23x | 0.15x | 0.26x | 0.28x | -0.21x | -0.00x |
| Interest Paid | 1.03M | 3.94M | 5.56M | 4.98M | 6.36M | 5.75M | 5.75M | 10.12M | 0 |
| Taxes Paid | 66K | 31K | 19K | 92K | 138K | 297K | 266K | 10.12M | 0 |
Health Catalyst, Inc. (HCAT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -29.95% | -48.25% | -38.39% | -29.02% | -29.84% | -18.99% | -58.26% |
| Return on Invested Capital (ROIC) | - | - | -17.49% | -23.46% | -23.6% | -19.26% | -17.85% | -10.19% | -32.94% |
| Gross Margin | 40.28% | 46.83% | 51.37% | 48.06% | 48.6% | 48.21% | 44.55% | 45.92% | 48.75% |
| Net Margin | -64.36% | -55.06% | -38.79% | -60.91% | -63.33% | -49.74% | -39.92% | -22.67% | -57.2% |
| Debt / Equity | - | - | 0.26x | 0.71x | 0.39x | 0.58x | 0.68x | 1.10x | 0.08x |
| Interest Coverage | -22.69x | -23.23x | -8.76x | -7.01x | -8.30x | -19.34x | -17.41x | -4.09x | - |
| FCF Conversion | 0.78x | 0.65x | 0.54x | 0.23x | 0.15x | 0.26x | 0.28x | -0.21x | -0.00x |
| Revenue Growth | - | 54.04% | 37.63% | 21.88% | 28.11% | 14.18% | 7.13% | 3.6% | 1.48% |
Health Catalyst, Inc. (HCAT) stock FAQ — growth, dividends, profitability & financials explained
Health Catalyst, Inc. (HCAT) reported $311.1M in revenue for fiscal year 2025. This represents a 326% increase from $73.1M in 2017.
Health Catalyst, Inc. (HCAT) grew revenue by 1.5% over the past year. Growth has been modest.
Health Catalyst, Inc. (HCAT) reported a net loss of $178.0M for fiscal year 2025.
Health Catalyst, Inc. (HCAT) has a return on equity (ROE) of -58.3%. Negative ROE indicates the company is unprofitable.
Health Catalyst, Inc. (HCAT) had negative free cash flow of $4.8M in fiscal year 2025, likely due to heavy capital investments.
Health Catalyst, Inc. (HCAT) financial analysis — history, returns, DCA and operating performance tools
Historical returns with dividends reinvested
Dollar cost averaging vs lump sum
Yield, growth, payout safety & DRIP
EPS trends, net income & profitability
Long-term charts & historical price data
Sales growth patterns & revenue breakdown
30 years of market, efficiency and balance-sheet ratios
DCF intrinsic value, peer multiples & estimates